New drug

New drug

VSY Biotechnology GmbH has announced that a new drug named TR-C 19 has been developed to treat COVID-19 by the company’s research centre. Studies have shown that TR-C 19 can neutralise the virus isolated under laboratory conditions, according to VSY. The drug is now at the authority approval stage for usage on voluntary COVID-19 patients and clinical trial. “[This] is one of the most meaningful projects that we have been developing,” said Dr Ercan Varlibas, Chairman of the Board of Directors of VSY Biotechnology GmbH. https://www.vsybiotechnology.com/

Latest Articles

Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

New Award to Encourage Research into Sustainable Practices

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.

AI Scribing and Telephone Management

Automating note-taking and call centres could boost practice efficiency.

AI Analysis and the Cornea

A combination of better imaging and AI deep learning could significantly improve corneal imaging and diagnosis.

Cooking a Feast for the Eyes

A cookbook to promote ocular health through thoughtful and traditional cuisine.

Need to Know: Spherical Aberration

Part three of this series examines spherical aberration and its influence on higher-order aberrations.

Generating AI’s Potential

How generative AI impacts medicine, society, and the environment.